Background. Campylobacter species are a leading cause of diarrheal disease globally with significant morbidity. Primary prevention efforts have yielded limited results. Rifaximin chemoprophylaxis decreases rates of travelers' diarrhea and may be suitable for high-risk persons. We assessed the efficacy of rifaximin in the controlled human infection model for Campylobacter jejuni.
Clinical Endpoints and Definitions
The primary outcome was campylobacteriosis within 144 hours of challenge, defined as moderate to severe diarrhea (≥4 loose stools or ≥401 g of loose stools in 24 hours) or fever (oral temperature ≥38.0°C) with an associated symptom of nausea, vomiting, abdominal cramps, tenesmus, or gross blood in ≥2 loose stools. An illness severity index was also estimated [20] .
Subject Recruitment and Inclusion and Exclusion Criteria
Healthy adults (18-50 years of age) were recruited from the mid-Atlantic area. All participants were briefed on study procedures, passed a comprehension test, signed informed consent, and met eligibility criteria. Subjects had no personal history of clinically significant diseases, immunosuppressive disorders, or medication. Subjects using antidiarrhea, anticonstipation, or antacid therapy, regularly ingesting raw milk, or with abnormal stool patterns were excluded. Subjects with a personal or family history of Guillain-Barré syndrome, inflammatory arthritis, or who were positive for HLA-B27 were excluded. Subjects with prior Campylobacter exposure history or serum immunoglobulin A (IgA) titer to C. jejuni CG8421 glycine extract (GE) >1:4000 were excluded [18] .
Investigational Products
Eligible subjects were randomized (1:1) to rifaximin or placebo. Each 550-mg tablet of rifaximin was cut into 4 pieces, each placed into a gelatin capsule with microcrystalline cellulose to fill the capsule. The placebo consisted of 4 identical gelatin capsules filled with microcrystalline cellulose. Investigators and subjects remained blinded for the study duration. Subjects received the investigational product twice daily for 4 days starting on day -1 unless they met the primary endpoint.
Challenge Strain and Administration
After 3 doses of rifaximin or placebo, subjects received the C. jejuni challenge inoculum on study day 0. Campylobacter jejuni strain CG8421 [18, 19] was grown on Mueller-Hinton agar and incubated under microaerophilic conditions at 40°C for 20.5 hours. Colonies were harvested and diluted in phosphate-buffered saline (PBS) to a targeted concentration of 5 × 10 5 CFU/mL based on the prior work with this strain [18, 20] . One milliliter was added to 30 mL sodium bicarbonate buffer (NaHCO 3 ) immediately prior to inoculation. One minute prior to inoculation, subjects ingested 120 mL of the same NaHCO 3 solution (2 grams per 150 mL). The dose was verified by enumeration of CFUs on Campylobacter CVA (cefoperazone, vancomycin, and amphotericin B) agar.
Clinical Monitoring and Management
During the inpatient period, a physician conducted daily medical interviews and examinations as described previously [18, 20] . Fluids were replaced orally or intravenously as clinically appropriate. Azithromycin (500 mg by mouth once daily) concurrently with ciprofloxacin (500 mg by mouth twice daily) was used for 5 days to treat all subjects starting 144 hours postchallenge unless meeting early treatment criteria. Early treatment criteria included severe diarrhea, moderate diarrhea for 2 days, mild or moderate diarrhea and ≥2 associated symptoms, or any illness for which the study physician thought necessitated early treatment. At discharge, all symptoms were resolved or resolving and subjects had ≥2 stools negative for C. jejuni. Subjects were provided remaining antibiotic treatment to be taken at home and were seen as outpatients 14, 21, 28, 35, 56 , and 84 days after challenge and contacted by telephone 6 months after challenge. For microbial recrudescence [20] [21] [22] , extra visits were necessary and ciprofloxacin and azithromycin were given for 10 additional days.
Microbiology
For culture, tips of swabs with fresh stool were placed in thioglycollate (Hardy Diagnostics, Santa Maria, California). The vials were incubated at 40°C (±2°C) until shipment to the Enteric Laboratory at JHU CIR. The swab was used to inoculate the first quadrant of 2 CVA plates followed by streaking with a sterile loop across the remaining 3 quadrants. Post-antibiotic administration, 200 µL of stool/thioglycollate solution was spread onto 4 CVA plates. The CVA plates were incubated for approximately 48 hours at 40°C (allowable range: 37°C-42°C) in a microaerobic environment generated by filling a polyethylene bag with Campylobacter gas (85% nitrogen, 10% carbon dioxide, and 5% oxygen) and sealing with a rubber band. Campylobacter was confirmed by oxidase and catalase tests and Gram stain. Frozen stools were extracted with the POWERsoil DNAisolation kit (MoBIO) following manufacturer protocol. The DNA were used to perform quantitative real-time polymerase chain reaction (qRT-PCR) using a C. jejuni-specific primer set lpxA F (5ʹ-ACAACTTGGTGACGATGTTGTA-3ʹ) and lpxA R (5ʹ-CAATCATGDGCDATATGASAATAHGCCAT-3ʹ) [23] . RT-PCR was performed on a QuantStudioT 6 (Applied Biosystems) using iTaqT Universal SYBR Green Supermix (BioRad). Extrapolation of CFUs was made by establishing a standard curve using C. jejuni DNA of known concentration. Linear regression between RT-PCR cycle thresholds vs DNA concentration was used to estimate the numbers of CFUs per gram. The theoretical number of chromosome copies per nanogram of DNA was estimated using 6 × 10 5 copies/ng of DNA.
Immune Response
Serum was analyzed for CG8421-specific responses using GE as previously described [24] . In brief, microtiter plates were coated overnight with GE at 3 µg protein/mL. After washing and blocking, serum was serially diluted, added to wells, and incubated for 2 hours at 37°C. Plates were washed and specific antibodies detected by addition of horseradish peroxidase-conjugated antihuman immunoglobulin G (IgG) or IgA (KPL, Gaithersburg, Maryland). TMB (eBiosciences, San Diego, California) was used as a detection reagent and the optical density at 450 nanometers was measured. The mean optical density of negative control wells (coating buffer alone) + 3 standard deviations was used to determine the endpoint titer. Frozen stool was thawed on ice and resuspended in extraction buffer (ethylenediaminetetraacetic acid [EDTA], soy trypsin inhibitor, bovine serum albumin, phenylmethysulfonyl fluoride in PBS) at 500 mg/mL. Samples were vortexed for 30 minutes, then centrifuged at 20 000g for 30 minutes at 4°C. Supernatants were collected and assayed for total IgA content. Samples were normalized to a starting concentration of 20 µg/ mL total IgA and serially diluted. GE-specific IgA was performed as described above. A response was defined as a ≥4-fold increase over the baseline values.
Whole blood was collected in EDTA to assess for Campylobacter-specific antibody-secreting cells (ASCs) and interferon gamma (IFN-γ) production. GE-specific ASCs were measured by coating nitrocellulose 96-well plates (MAHAS4510, Millipore, Billerica, Massachusetts) with 3 µg/ mL CG8421 GE and incubating 5 × Campylobacter-specific IFN-γ production was measured by stimulating 10 5 PBMCs with media alone or 10 5 CFUs of fixed CG8421 cells at 37°C for 72 hours. Culture supernatants were collected and analyzed with a Bio-Plex Pro Human Cytokine IFN-γ Magnetic Bead kit (Bio-Rad, Hercules, California). IFN-γ produced by media-alone wells was subtracted from CG8421-stimulated wells to estimate Campylobacter-specific IFN-γ. IFN-γ responders were defined as a ≥2-fold increase over baseline per 10 5 PBMCs.
Statistical Analysis
Dichotomous results were analyzed using Fisher exact test and quantitative parameters using Wilcoxon rank-sum test for variables not normally distributed. Serologic titers were log 10 -transformed for statistical analysis. Statistical analyses were performed with SAS version 9.4 software (SAS Institute, Cary, North Carolina). Statistical significance was set at P < .05.
Power
Using a 2-group continuity-adjusted χ 2 test with a 2-sided α = .05, a targeted rifaximin efficacy of 60% [14] , and a campylobacteriosis rate of 93.3% in placebo recipients [18, 20] , a sample size of 14 subjects per group yielded >80% power to detect a significant difference in the rate of campylobacteriosis.
Regulatory Approvals
The study protocol was approved by the Naval Medical Research Center and the Western institutional review boards in compliance with all applicable local, federal, and Department of Defense regulations governing the protection of human subjects. The study was registered at ClinicalTrials.gov on 29 October 2014 as NCT02280044.
RESULTS
Of 74 screened subjects, 44 were excluded, 68.2% due to high serum anti-GE IgA titers (Figure 1) . A total of 28 subjects (13 placebo, 15 rifaximin) received the challenge inoculum on day 0. Subjects were predominately male (71.4%) and African American (92.9%) with a median age of 30 years ( ; P = .6). There was a slight decrease in the total number of loose stools (rifaximin, 12 vs placebo, 18) and a significant decrease in total weight (rifaximin, 1437 g vs placebo, 2565 g) of loose stools in rifaximin recipients compared with placebo (P = .13 and P = .05, respectively). All subjects shed the challenge strain with no difference (P = .9) in maximum shedding between placebo (10 7.2 CFU/g of stool) and rifaximin (10 7.5 CFU/g of stool) recipients. There was no evidence of acquired antirifampicin resistance in subjects receiving rifaximin (data not shown). Post-azithromycin/ ciprofloxacin treatment, all subjects were repeatedly stool culture negative for Campylobacter. Asymptomatic recrudescence was observed in 5 subjects, 2 (13.1%) receiving rifaximin (both on day 56) and 3 (23.1%) receiving placebo (1 on day 21 and 2 on day 56). Of the recrudescent cases, 80.0% were repeatedly culture negative following additional combined antibiotic treatment for 10 days. One placebo recipient experienced a second recrudescence 56 days after starting the second dual antibiotic course (77 days after challenge). The subject was started on amoxicillin-clavulanate for 7 days with a probiotic (Lactinex, BD Diagnostic Systems, Sparks, Maryland); however, treatment compliance was questionable and stool cultures remained positive 20 days after initiation. The subject was subsequently lost to follow-up. All isolates remained sensitive to azithromycin and ciprofloxacin. Serologic responses were observed in 92.9% (IgA) and 75.0% (IgG) of challenged subjects. Responses peaked on days 9 and 14, respectively (Figure 2A ). Fecal IgA response was observed in 85.7% of subjects, with no difference in the frequency (P = .7) or magnitude (P = 1.0) of the responses by treatment. Responses peaked on day 9, decreased over time, but remained elevated through day 84 ( Figure 2B) . ASC responses to GE were observed in 75.0% (IgG) and 96.4% (IgA) of subjects with no difference across study groups. The maximum number of ASCs per 10 6 PBMCs varied greatly ( Figure 2C ). Campylobacter-specific IFN-γ responses were observed in 60.7% of subjects, with a median fold increase of 5.0 ( Figure 3 ). There was no difference in response frequency (P = 1.0) or magnitude (P = .8) across treatments.
DISCUSSION
The use of the C. jejuni CHIM provided a clear and specific result and demonstrated that rifaximin does not protect against campylobacteriosis in this model. In contrast, 2 separate systematic reviews of the prophylactic efficacy of rifaximin have estimated efficacy of approximately 60% against TD [14, 25] ; however, many of these studies were in diarrheagenic E. coli predominate regions [4, 26] . A 48% efficacy was observed in a trial of rifaximin prophylaxis (200 mg twice daily) in travelers to Asia, a region with higher rates of Campylobacter-attributed TD [27] . The dose for this study, 550 mg twice daily, was selected to optimize efficacy given the findings from travelers to Asia. Perhaps more akin to this study, albeit at a different antibiotic dose, rifaximin provided 100% protection from shigellosis in the CHIM of Shigella flexneri [17] . These findings may be partially explainable by rifaximin pharmacology and Campylobacter infection. Hopkins et al tested the susceptibility to rifaximin of several enteropathogens recovered from travelers returning to the United Kingdom and showed that although rifaximin appeared to have broad coverage against most organisms, Campylobacter appeared to be broadly resistant (≥128 µg/mL) in vitro [28] . However, Gomi et al reported a minimum inhibitory concentration 90 (MIC 90 ) for rifaximin of 32 µg/mL using C. jejuni recovered from individuals with TD from Kenya, and Novoa-Farias et al reported that 100% of campylobacteriosis isolates in Mexico were susceptible to rifaximin at <200 µg/mL [29, 30] . The pharmacological properties of rifaximin precluded determination of the CG8421 minimum inhibitory concentration; however, the minimum inhibitory concentration 50 (MIC 50 ) against rifampicin, an absorbable form of rifaximin, was 32 µg/mL (data not shown). Nonetheless, the applicability of these in vitro assays is unclear given the high levels of fecal concentrations of rifaximin following repeated oral dosing. For example, in stool following a 3-day 400-mg twicedaily dosing, there is a mean concentration of 8000 μg rifaximin/ mL of stool at the therapeutic site of action [31] . We utilized a 550-mg rifaximin dose twice daily approximately 12 hours apart to maximize the potential efficacy against campylobacteriosis. Rifaximin was given with meals as it was anticipated that free molecular rifaximin would be enhanced in the small intestine following a meal [32] . It was presumed that rifaximin would intercept the pathogen in transit to the large intestine; however, rifaximin is water insoluble and requires physiological concentrations of bile acid to be active against diarrheal pathogens [33] . The primary site of human Campylobacter infection is the distal ileum and colon [34] [35] [36] . As such, decreased drug bioavailability at the infection site may have negatively affected efficacy. Rifamycin formulations targeting colonic bioavailability are under development and may be more effective [37] . However, rifaximin prevented shigellosis in the CHIM where the colon is an active site of infection, pointing to potential differences in pathogen susceptibility or antibiotic action during pathogen transit of the small intestine. Interestingly, in the shigellosis model, rifaximin-treated subjects did not develop IgA ASCs, a standard mucosal-mediated immune response, whereas placebo subjects had a geometric mean of 73 IgA ASCs per 10 6 PBMCs to anti-S. flexneri lipopolysaccharide (P = .008). In contrast, we observed no difference in ASC responses between placebo-and rifaximin-treated subjects. The CG8421 CHIM-induced disease is comparable to prior studies despite a modification in immunologic screening from prior studies with this strain, which excluded subjects with an IFN-γ level >400 pg/mL after in vitro stimulation of PBMCs with formalin-fixed CG8421 whole cells [18, 20] . Such screening would have excluded 22 of 28 (78.6%) of our subjects; however, there was no difference in disease endpoints across levels of baseline IFN-γ (data not shown). Of note, C. jejuni 81-176 CHIM confers 100% short-term protection on homologous rechallenge compared to the lack of protection in the CG8421 CHIM, highlighting questions on protective immunity and immunologic screening [20, 24] .
We observed an 18% microbial recrudescence rate, higher than seen previously (4%; P = .03) and not associated with treatment group. It is unclear whether this represents a true increase in recrudescence or is due to enhanced microbiological methods. Prior studies maintained whole stool specimens at refrigerator temperature until plating [18, 20] . Our use of short-term incubation in thioglycollate broth may have enhanced our ability to detect recrudescent events. Importantly, all subjects appeared to be Campylobacter negative prior to discharge. Additionally, all subjects remained asymptomatic during their recrudescence. Microbial recrudescence of Campylobacter following treatment with appropriate antibiotics was first described by Baqar et al in a CHIM with C. jejuni CG8421 [21] . It remains unclear whether this phenomenon occurs as part of the natural course of C. jejuni infection. The experience with the CG8421 CHIM has shown the majority, but not all, to be asymptomatic, so conceivably unrecognized recrudescence occurs in a minority of treated infections. The recrudescent bacteria likely are capable of securing a protective niche during the period of high-dose antibiotic exposure, particularly given that subjects are treated with multiple doses of both azithromycin and ciprofloxacin, which provide high fecal and intracellular drug levels with long half-lives. Among 9 subjects with recrudescence, there has been a single emergent antibiotic resistance to azithromycin and none against ciprofloxacin, a well-described phenomenon [22, 38] . Recrudescence may play a role in recurrent infections and sustained colonization among developing-world children; however, there are no reports or studies of Campylobacter recrudescence following community-acquired exposures [12] . Follow-up studies of naturally acquired Campylobacter infections are needed to determine the extent to which recrudescent infections occur.
CONCLUSIONS
Despite the high rifaximin dose, no efficacy against campylobacteriosis was observed in this CHIM. While disappointing, the CHIM model is a robust infection with inocula exceeding natural infection, and field studies with higher rifaximin doses in Campylobacter predominant regions are under way. While chemoprophylaxis for TD is a subject of debate, there are circumstances in which disease mitigation may tip the risk-benefit equipoise. Recent guidelines critically appraised the evidence of rifaximin chemoprophylaxis effectiveness in the context of potential benefits and risks [39, 40] . Recommendations continue to support short-term antibiotics to prevent TD in high-risk groups potentially susceptible to serious health consequences, or in whom illness may have negative travel implications. Rifaximin may represent a safer alternative to fluoroquinolones; however, potential lack of efficacy against Campylobacter-attributed TD may limit its utility. Perhaps most importantly, given the acute illness severity and the growing number of attributable chronic long-term health consequences of Campylobacter infection [41] , primary prevention strategies, such as vaccines, are clearly needed.
